{"id":53844,"date":"2023-02-13T11:07:04","date_gmt":"2023-02-13T10:07:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/"},"modified":"2023-02-13T11:07:04","modified_gmt":"2023-02-13T10:07:04","slug":"legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/","title":{"rendered":"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Preclinical results demonstrate the differentiation in efficacy and safety of this first-in-class candidate<\/b>\n<\/li>\n<li>\n<b>LegoChemBio to advance this potentially fifth LegoChemBio platform-generated ADC candidate into clinic<\/b>\n<\/li>\n<\/ul>\n<p>\n\u00a0\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230213005251\/en\/1711588\/4\/Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230213005251\/en\/1711588\/21\/Logo.jpg\"><\/a><\/p>\n<p>DAEJEON, South Korea&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/ADC?src=hash\" target=\"_blank\" rel=\"noopener\">#ADC<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.legochembio.com%2Findex.php%3Flang%3De&amp;esheet=53316876&amp;newsitemid=20230213005251&amp;lan=en-US&amp;anchor=LegoChem+Biosciences+Inc.&amp;index=1&amp;md5=209edcef0c2682fe90c45f0ff2ae2ea6\" rel=\"nofollow noopener\" shape=\"rect\">LegoChem Biosciences Inc.<\/a> (KOSDAQ:141080) (hereinafter \u201cLegoChemBio\u201d) announced on February 13, 2023 a license agreement with <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.elthera.com%2F&amp;esheet=53316876&amp;newsitemid=20230213005251&amp;lan=en-US&amp;anchor=Elthera+AG&amp;index=2&amp;md5=0c2d1c641a65ef1ed6734b516edb5be2\" rel=\"nofollow noopener\" shape=\"rect\">Elthera AG<\/a>, a biotechnology company in Switzerland, to develop and commercialize a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by Elthera.\n<\/p>\n<p>\nThe licensed asset is a monoclonal antibody with a target expressed in a variety of solid tumors including pancreatic, ovarian, breast, lung, and colorectal cancer. Under the terms of the agreement, LegoChemBio will be responsible for the future development and commercialization of any products incorporating this antibody.\n<\/p>\n<p>\nElthera will receive an upfront payment and is eligible to receive progress-dependent development and regulatory milestone payments as well as cumulative commercial milestone payments. Elthera will additionally receive royalties on net product sales.\n<\/p>\n<p>\n\u201cWe are very pleased to enter into this license agreement with LegoChemBio, a global ADC company with industry-leading ADC technology,\u201d said Anne Schmidt, CEO of Elthera. \u201cThis agreement is the result of a fruitful collaboration with LegoChemBio, demonstrating the outstanding quality and therapeutic potential of our antibody. The combination with LegoChemBio\u2019s ConjuAll technology generates a well-differentiated first-in class ADC with a wide therapeutic window that has the potential to provide new treatment options for a large number of solid tumors.\u201d\n<\/p>\n<p>\n\u201cWe are pleased to enter this agreement with Elthera as we continue to expand our toolbox to maximize the value of our ADC platform. We look forward to bringing this innovative ADC drug into the clinic as LCB\u2019s fifth ADC,\u201d said Dr. Yong-Zu Kim, CEO of LegoChemBio.\n<\/p>\n<p>\n<b>About LegoChem Biosciences<\/b>\n<\/p>\n<p>\nLegoChem Biosciences (LCB, KOSDAQ: 141080) is a clinical-stage biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry and ADC platform technology ConjuAll\u2122. Since its foundation in 2006, LCB has focused on the research and development of Antibody-Drug-Conjugates (ADCs), anticancer therapeutics, antibiotics and anti-fibrotic based on proprietary platform technologies.\n<\/p>\n<p>\n<b>About Elthera<\/b>\n<\/p>\n<p>\nElthera AG, a privately held biotechnology company based in Switzerland, is developing first in class antibodies for the diagnosis and treatment of patients with cancer, using a personalized health care approach. Elthera has received funding from the European Union&#8217;s Horizon 2020 research and innovation programme under the grant agreement No 858753 and co-funding by the Innosuisse-Swiss Innovation Agency and the European Union under the Eurostars project E!114014.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nLegoChem Biosciences<br \/>\n<br \/>Daeyoung Jeong<br \/>\n<br \/>+82-42-861-0688<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#108;&#x74;&#x6f;&#x3a;jd&#121;&#64;&#x6c;&#x65;&#x67;&#x6f;ch&#101;&#109;&#x62;&#x69;&#x6f;&#x2e;c&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6a;&#x64;&#x79;&#x40;&#x6c;&#x65;&#103;&#111;&#99;&#104;embi&#x6f;&#x2e;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Preclinical results demonstrate the differentiation in efficacy and safety of this first-in-class candidate LegoChemBio to advance this potentially fifth LegoChemBio platform-generated ADC candidate into clinic \u00a0 DAEJEON, South Korea&#8211;(BUSINESS WIRE)&#8211;#ADC&#8212;LegoChem Biosciences Inc. (KOSDAQ:141080) (hereinafter \u201cLegoChemBio\u201d) announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology company in Switzerland, to develop and commercialize &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53844","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Preclinical results demonstrate the differentiation in efficacy and safety of this first-in-class candidate LegoChemBio to advance this potentially fifth LegoChemBio platform-generated ADC candidate into clinic \u00a0 DAEJEON, South Korea&#8211;(BUSINESS WIRE)&#8211;#ADC&#8212;LegoChem Biosciences Inc. (KOSDAQ:141080) (hereinafter \u201cLegoChemBio\u201d) announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology company in Switzerland, to develop and commercialize ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-13T10:07:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230213005251\/en\/1711588\/21\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera\",\"datePublished\":\"2023-02-13T10:07:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/\"},\"wordCount\":424,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230213005251\\\/en\\\/1711588\\\/21\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/\",\"name\":\"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230213005251\\\/en\\\/1711588\\\/21\\\/Logo.jpg\",\"datePublished\":\"2023-02-13T10:07:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230213005251\\\/en\\\/1711588\\\/21\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230213005251\\\/en\\\/1711588\\\/21\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/","og_locale":"en_US","og_type":"article","og_title":"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera - Pharma Trend","og_description":"Preclinical results demonstrate the differentiation in efficacy and safety of this first-in-class candidate LegoChemBio to advance this potentially fifth LegoChemBio platform-generated ADC candidate into clinic \u00a0 DAEJEON, South Korea&#8211;(BUSINESS WIRE)&#8211;#ADC&#8212;LegoChem Biosciences Inc. (KOSDAQ:141080) (hereinafter \u201cLegoChemBio\u201d) announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology company in Switzerland, to develop and commercialize ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-13T10:07:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230213005251\/en\/1711588\/21\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera","datePublished":"2023-02-13T10:07:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/"},"wordCount":424,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230213005251\/en\/1711588\/21\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/","url":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/","name":"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230213005251\/en\/1711588\/21\/Logo.jpg","datePublished":"2023-02-13T10:07:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230213005251\/en\/1711588\/21\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230213005251\/en\/1711588\/21\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53844"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53844\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}